Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disufenton/acetylcysteine

Drug Profile

Disufenton/acetylcysteine

Alternative Names: Disufenton/N-acetylcysteine; HPN-07/NAC; NHPN-1010; NXY-059/NAC

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hough Ear Institute Scientists; Oklahoma Medical Research Foundation
  • Developer Hough Ear Institute Scientists; Otologic Pharmaceutics
  • Class Benzenesulfonates; Nitrogen oxides; Small molecules; Sulfur amino acids
  • Mechanism of Action Free radical inhibitors; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sensorineural hearing loss; Tinnitus; Traumatic brain injuries

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for research development in Traumatic-brain-injuries in USA (PO, Capsule)
  • 28 Aug 2022 No recent reports of development identified for research development in Tinnitus in USA (PO, Capsule)
  • 17 Feb 2020 Disufenton/acetylcysteine is still in early research phase for Tinnitus in USA (PO, Capsule) (Otologic pharmaceutics pipeline, February 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top